Kamada Ltd. (KMDA)
USD 5.76
(-1.37%)
USD 5.76
(-1.37%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 10.06 Million USD | 778.98% |
| 2022 | -1.64 Million USD | -309.73% |
| 2021 | -401 Thousand USD | -102.08% |
| 2020 | 19.23 Million USD | -15.57% |
| 2019 | 22.78 Million USD | 18.3% |
| 2018 | 19.25 Million USD | 158.72% |
| 2017 | 7.44 Million USD | 227.44% |
| 2016 | -5.84 Million USD | 48.87% |
| 2015 | -11.42 Million USD | -4.79% |
| 2014 | -10.9 Million USD | -394.65% |
| 2013 | 3.7 Million USD | -12.69% |
| 2012 | 4.23 Million USD | 282.88% |
| 2011 | -2.31 Million USD | 78.41% |
| 2010 | -10.73 Million USD | 34.44% |
| 2009 | -16.37 Million USD | 3.92% |
| 2008 | -17.04 Million USD | -4.45% |
| 2007 | -16.31 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 5.56 Million USD | 40.9% |
| 2024 Q1 | 4 Million USD | 37.03% |
| 2023 Q4 | 2.92 Million USD | -33.12% |
| 2023 FY | 11.15 Million USD | 778.98% |
| 2023 Q2 | 2.63 Million USD | 281.82% |
| 2023 Q3 | 4.36 Million USD | 66.02% |
| 2023 Q1 | -1.44 Million USD | -136.01% |
| 2022 Q4 | 4.01 Million USD | 641.33% |
| 2022 Q3 | 542 Thousand USD | 123.63% |
| 2022 FY | -1.64 Million USD | -309.73% |
| 2022 Q1 | -1.76 Million USD | 46.64% |
| 2022 Q2 | -2.29 Million USD | -30.19% |
| 2021 Q4 | -3.3 Million USD | -310.7% |
| 2021 Q2 | 1.04 Million USD | -55.75% |
| 2021 Q3 | -804 Thousand USD | -176.86% |
| 2021 FY | -401 Thousand USD | -102.08% |
| 2021 Q1 | 2.36 Million USD | -10.76% |
| 2020 Q4 | 2.64 Million USD | -65.88% |
| 2020 Q2 | 3.97 Million USD | -18.04% |
| 2020 Q1 | 4.85 Million USD | -11.58% |
| 2020 Q3 | 7.76 Million USD | 95.3% |
| 2020 FY | 19.23 Million USD | -15.57% |
| 2019 FY | 22.78 Million USD | 18.3% |
| 2019 Q3 | 5.69 Million USD | -10.89% |
| 2019 Q4 | 5.48 Million USD | -3.72% |
| 2019 Q2 | 6.39 Million USD | 22.73% |
| 2019 Q1 | 5.2 Million USD | -66.14% |
| 2018 Q1 | 1.22 Million USD | -80.95% |
| 2018 Q4 | 15.38 Million USD | 709.51% |
| 2018 Q3 | -2.52 Million USD | -148.81% |
| 2018 FY | 19.25 Million USD | 158.72% |
| 2018 Q2 | 5.17 Million USD | 321.09% |
| 2017 Q3 | -314 Thousand USD | -106.25% |
| 2017 FY | 7.44 Million USD | 227.44% |
| 2017 Q4 | 6.44 Million USD | 2152.55% |
| 2017 Q2 | 5.02 Million USD | 235.38% |
| 2017 Q1 | -3.71 Million USD | -95.93% |
| 2016 FY | -5.84 Million USD | 48.87% |
| 2016 Q1 | -1.97 Million USD | -349.43% |
| 2016 Q2 | -590 Thousand USD | 70.17% |
| 2016 Q3 | -1.01 Million USD | -72.71% |
| 2016 Q4 | -1.89 Million USD | -85.87% |
| 2015 Q2 | -2.45 Million USD | 57.29% |
| 2015 Q4 | 793 Thousand USD | 119.77% |
| 2015 Q3 | -4.01 Million USD | -63.31% |
| 2015 Q1 | -5.75 Million USD | -362.32% |
| 2015 FY | -11.42 Million USD | -4.79% |
| 2014 Q3 | -2.49 Million USD | 68.35% |
| 2014 Q1 | -2.7 Million USD | -212.89% |
| 2014 FY | -10.9 Million USD | -394.65% |
| 2014 Q2 | -7.89 Million USD | -191.47% |
| 2014 Q4 | 2.19 Million USD | 187.79% |
| 2013 Q3 | 958 Thousand USD | -41.87% |
| 2013 Q2 | 1.64 Million USD | 226.38% |
| 2013 FY | 3.7 Million USD | -12.69% |
| 2013 Q4 | 2.39 Million USD | 150.31% |
| 2013 Q1 | -1.3 Million USD | -136.46% |
| 2012 Q4 | 3.57 Million USD | 161.67% |
| 2012 FY | 4.23 Million USD | 282.88% |
| 2012 Q2 | -1.04 Million USD | 0.0% |
| 2012 Q3 | 1.36 Million USD | 231.06% |
| 2011 FY | -2.31 Million USD | 78.41% |
| 2010 FY | -10.73 Million USD | 34.44% |
| 2009 FY | -16.37 Million USD | 3.92% |
| 2008 FY | -17.04 Million USD | -4.45% |
| 2007 FY | -16.31 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Journey Medical Corporation | -2.07 Million USD | 585.48% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 78.574% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 166.64% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 88.521% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 310.311% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 310.311% |
| SCYNEXIS, Inc. | 72.66 Million USD | 86.151% |
| Safety Shot Inc | -12.18 Million USD | 182.599% |
| Alpha Teknova, Inc. | -35.56 Million USD | 128.299% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 93.972% |
| Bright Green Corporation | -8.89 Million USD | 213.188% |
| Dynavax Technologies Corporation | -37.02 Million USD | 127.179% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 106.469% |
| Cosmos Health Inc. | -21.83 Million USD | 146.099% |
| PainReform Ltd. | -9.58 Million USD | 205.008% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 500.125% |
| Embecta Corp. | 221.5 Million USD | 95.456% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 106.314% |
| Procaps Group, S.A. | 38.97 Million USD | 74.177% |
| Theratechnologies Inc. | -10.62 Million USD | 194.702% |
| Harrow Health, Inc. | 580 Thousand USD | -1635.172% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 314.082% |
| Biofrontera Inc. | -22.67 Million USD | 144.38% |
| DURECT Corporation | -36.88 Million USD | 127.286% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 291.004% |
| Cronos Group Inc. | -81.37 Million USD | 112.367% |
| OptiNose, Inc. | -22.74 Million USD | 144.241% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 95.186% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 125.704% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 20.329% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 19.649% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | 332.086% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 262.04% |
| Radius Health, Inc. | -3.92 Million USD | 356.408% |
| Universe Pharmaceuticals INC | -3.52 Million USD | 385.36% |
| ProPhase Labs, Inc. | -21.61 Million USD | 146.565% |
| Phibro Animal Health Corporation | 53.31 Million USD | 81.124% |
| Procaps Group S.A. | 52.32 Million USD | 80.766% |
| Alvotech | -354.86 Million USD | 102.836% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 218.08% |
| Viatris Inc. | 766.2 Million USD | 98.687% |
| Rockwell Medical, Inc. | -6.67 Million USD | 250.885% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 291.549% |
| SIGA Technologies, Inc. | 83.62 Million USD | 87.965% |
| Tilray Brands, Inc. | -174.74 Million USD | 105.759% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | -7.856% |
| Shineco, Inc. | -17.06 Million USD | 158.971% |
| PetIQ, Inc. | 60.01 Million USD | 83.231% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 312.467% |
| Incannex Healthcare Limited | -30.04 Million USD | 133.501% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 95.989% |
| Alimera Sciences, Inc. | -1.47 Million USD | 784.16% |
| Silver Spike Investment Corp. | 7.34 Million USD | -37.11% |
| Assertio Holdings, Inc. | -243.53 Million USD | 104.132% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 270.797% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 173.906% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 164.538% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 150.194% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 107.301% |
| Hempacco Co., Inc. | -8.81 Million USD | 214.204% |
| Talphera, Inc. | -16.88 Million USD | 159.589% |
| Alvotech | -354.86 Million USD | 102.836% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 81.173% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 97.24% |
| Currenc Group, Inc. | -6.64 Million USD | 251.434% |
| Indivior PLC | -4 Million USD | 351.6% |
| Evoke Pharma, Inc. | -7.43 Million USD | 235.435% |
| Flora Growth Corp. | -50.35 Million USD | 119.986% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 150.194% |
| Evolus, Inc. | -49.23 Million USD | 120.442% |
| HUTCHMED (China) Limited | 18.37 Million USD | 45.23% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 94.891% |
| Akanda Corp. | -10.05 Million USD | 200.126% |